---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-028869"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T20:41:00.149892+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Erasca extends cash runway to H2 2025, accelerates naporafenib and ERAS-601 readouts

## Summary
- Cash runway extended from H1 2025 to H2 2025; resources focused on naporafenib and ERAS-007/601 sub-studies.
- SEACRAFT-1 (naporafenib in RAS Q61X solid tumors) data readout accelerated to Q2-Q4 2024 from H2 2024-H1 2025.
- FLAGSHP-1 (ERAS-601 in HPV-neg HNSCC) data readout accelerated to H1 2024 from calendar year 2024.
- HERKULES-3 (ERAS-007/601 in BRAFm CRC) data readout affirmed for H2 2023-H1 2024.
- Other milestones: SEACRAFT-2 Ph3 FPD in NRASm melanoma H1 2024, THUNDERBBOLT-1 Ph1 data in rGBM H2 2023.

## SEC filing metadata
- accession: 0001193125-23-028869
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312523028869/0001193125-23-028869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312523028869/d382775d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-028869
- JSON: https://secwatch.observer/filing/0001193125-23-028869.json
- Plain text: https://secwatch.observer/filing/0001193125-23-028869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.